PT  - JOURNAL ARTICLE
AU  - Ahmed, Faruque
AU  - Nowalk, Mary Patricia
AU  - Zimmerman, Richard K.
AU  - Bear, Todd
AU  - Grijalva, Carlos G.
AU  - Talbot, H. Keipp
AU  - Florea, Ana
AU  - Tartof, Sara Y.
AU  - Gaglani, Manjusha
AU  - Smith, Michael
AU  - McLean, Huong Q.
AU  - King, Jennifer P.
AU  - Martin, Emily T.
AU  - Monto, Arnold S.
AU  - Phillips, C. Hallie
AU  - Wernli, Karen J.
AU  - Flannery, Brendan
AU  - Chung, Jessie R.
AU  - Uzicanin, Amra
TI  - Work Attendance during Acute Respiratory Illness Before and During the COVID-19 Pandemic, United States, 2018–2022
AID  - 10.1101/2023.08.03.23293611
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.08.03.23293611
4099  - http://medrxiv.org/content/early/2023/08/06/2023.08.03.23293611.short
4100  - http://medrxiv.org/content/early/2023/08/06/2023.08.03.23293611.full
AB  - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and influenza viruses can be transmitted by infected persons who are pre-symptomatic or symptomatic. To assess impact of the COVID-19 pandemic on work attendance during illness, we analyzed prospectively collected data from persons with acute respiratory illness (ARI) enrolled in a multi-state study during 2018–2022. Persons with prior experience working from home were significantly less likely than those without this experience to work onsite on the day before illness and during the first 3 days of illness; the effect was more pronounced for the COVID-19 pandemic period than the pre-pandemic influenza seasons. Persons with influenza or COVID-19 were significantly less likely to work onsite than persons with other ARIs. Among persons for whom positive COVID-19 test results were available by the second or third day of illness, few worked onsite. Work-from-home policies may reduce the likelihood of workplace exposures to respiratory viruses.Article’s summary line Work-from-home policies may reduce the likelihood of workplace exposures to SARS-CoV-2 and influenza viruses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported through cooperative agreements funded by the US Centers for Disease Control and Prevention and by infrastructure funding from the National Institutes of Health (UL1 TR001857) at the University of Pittsburgh.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of the US Centers for Disease Control and Prevention (CDC) gave approval for this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data produced in the study are not available online.